164 related articles for article (PubMed ID: 27304657)
1. Does progesterone therapy increase nuchal translucency in women with threatened miscarriage?
Keçecioğlu M; Tokmak A; Keçecioğlu TS; Akselim B; Karakaya BK; Taşçı Y
Ginekol Pol; 2016; 87(5):390-4. PubMed ID: 27304657
[TBL] [Abstract][Full Text] [Related]
2. The effects of progesterone treatment on nuchal translucency in women with threatened miscarriage.
Karadağ C; Yoldemir T; Demircan S; Çalışkan E
J Obstet Gynaecol; 2021 May; 41(4):601-604. PubMed ID: 32811232
[TBL] [Abstract][Full Text] [Related]
3. The effects of exogenous oral micronized progesterone on first trimester aneuploidy screening markers in women with threatened miscarriage: a matched case control study.
Karaca I; Erdoğan ŞV; Doğan K; Alay I; Ince O; Yıldırım Karaca S; Comba C; Bahceci E; Erdoğan A; Ozturk E; Ekin M
J Matern Fetal Neonatal Med; 2022 Apr; 35(7):1224-1229. PubMed ID: 32456488
[TBL] [Abstract][Full Text] [Related]
4. Effects of exogenous progesterone on fetal nuchal translucency: an observational prospective study.
Giorlandino C; Cignini P; Padula F; Giannarelli D; d'Emidio L; Aloisi A; Plotti F; Angioli R
Am J Obstet Gynecol; 2015 Mar; 212(3):335.e1-7. PubMed ID: 25305408
[TBL] [Abstract][Full Text] [Related]
5. The effects of dydrogesterone treatment on first-trimester aneuploidy screening markers and nuchal translucency in women with threatened miscarriage.
Yıldız E; Timur B
Turk J Obstet Gynecol; 2023 Mar; 20(1):16-21. PubMed ID: 36908009
[TBL] [Abstract][Full Text] [Related]
6. The value of placental protein 13, β-human chorionic gonadotropin and progesterone in the prediction of miscarriages in threatened miscarriage patients.
Yalçin I; Taşkin S; Pabuçcu EG; Söylemez F
J Obstet Gynaecol; 2015 Apr; 35(3):283-6. PubMed ID: 25153203
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of progesterone on threatened miscarriage: Difference in drug types.
Wang XX; Luo Q; Bai WP
J Obstet Gynaecol Res; 2019 Apr; 45(4):794-802. PubMed ID: 30632226
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].
Borowski D; Czuba B; Cnota W; Hincz P; Czekierdowski A; Gajewska J; Jaczyńska R; Ceran A; Włoch A; Wyrwas D; Wiełgoś M; Szymusik I; Szaflik K; Sodowski K
Ginekol Pol; 2007 May; 78(5):384-7. PubMed ID: 17867331
[TBL] [Abstract][Full Text] [Related]
9. Prenatal screening for fetal aneuploidy in singleton pregnancies.
Chitayat D; Langlois S; Douglas Wilson R; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
[TBL] [Abstract][Full Text] [Related]
10. [The role of fetal nuchal translucency (NT) and ductus venosus blood flow (DV) in the detection of congenital heart defects].
Baś-Budecka E; Perenc M; Sieroszewski P
Ginekol Pol; 2010 Apr; 81(4):272-6. PubMed ID: 20476599
[TBL] [Abstract][Full Text] [Related]
11. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
[TBL] [Abstract][Full Text] [Related]
12. Miscarriage after a normal scan at 12-14 gestational weeks in women at low risk of carrying a fetus with chromosomal anomaly according to nuchal translucency screening.
Westin M; Källén K; Saltvedt S; Almström H; Grunewald C; Valentin L
Ultrasound Obstet Gynecol; 2007 Oct; 30(5):728-36. PubMed ID: 17823976
[TBL] [Abstract][Full Text] [Related]
13. Construction of machine learning tools to predict threatened miscarriage in the first trimester based on AEA, progesterone and β-hCG in China: a multicentre, observational, case-control study.
Huang J; Lv P; Lian Y; Zhang M; Ge X; Li S; Pan Y; Zhao J; Xu Y; Tang H; Li N; Zhang Z
BMC Pregnancy Childbirth; 2022 Sep; 22(1):697. PubMed ID: 36085038
[TBL] [Abstract][Full Text] [Related]
14. [Distribution and normal reference range of fetal nuchal translucency thickness in Kunming pregnant women in the first trimester].
Sun Q; Xu J; Hu SQ; Chen M; Ma RM; Lau TK; Zhang L; Xiao X; Qian Y; Guo Z
Zhonghua Fu Chan Ke Za Zhi; 2012 Jul; 47(7):514-7. PubMed ID: 23141162
[TBL] [Abstract][Full Text] [Related]
15. Fetal nuchal translucency thickness evaluation in the overweight and obese gravida.
Thornburg LL; Mulconry M; Post A; Carpenter A; Grace D; Pressman EK
Ultrasound Obstet Gynecol; 2009 Jun; 33(6):665-9. PubMed ID: 19479678
[TBL] [Abstract][Full Text] [Related]
16. Real-world pharmacological treatment patterns of patients with threatened miscarriage in China from 2014 to 2020: A cross-sectional analysis.
Pang YY; Ma CL
J Clin Pharm Ther; 2022 Feb; 47(2):228-236. PubMed ID: 34704273
[TBL] [Abstract][Full Text] [Related]
17. Can single progesterone concentration predict miscarriage in early pregnant women with threatened miscarriage: a systematic review and meta-analysis.
Gong Y; Jiang T; Sun Y; Wu GL; Han BW; Shi Y; Guan S; Li J
BMC Pregnancy Childbirth; 2024 Feb; 24(1):133. PubMed ID: 38350926
[TBL] [Abstract][Full Text] [Related]
18. Prospective audit of a one-centre combined nuchal translucency and triple test programme for the detection of trisomy 21.
Babbur V; Lees CC; Goodburn SF; Morris N; Breeze AC; Hackett GA
Prenat Diagn; 2005 Jun; 25(6):465-9. PubMed ID: 15966036
[TBL] [Abstract][Full Text] [Related]
19. Second-trimester soft markers: relation to first-trimester nuchal translucency in unaffected pregnancies.
Miguelez J; De Lourdes Brizot M; Liao AW; De Carvalho MH; Zugaib M
Ultrasound Obstet Gynecol; 2012 Mar; 39(3):274-8. PubMed ID: 21484908
[TBL] [Abstract][Full Text] [Related]
20. SURUSS in perspective.
Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
